碘-125粒子近距离治疗用于宫颈癌体外放疗后非中央型盆腔复发
研究纳入2015年6月至2022年4月间32例患者共41个病灶,接受CT和/或3D打印模板引导下碘-125粒子植入,中位剂量100 Gy(范围80-120 Gy)。中位随访48.52个月,6、12、24个月局部控制率分别为88.0%、63.2%、42.1%,1年、2年生存率分别为36%、33%,中位生存时间13.26个月,未发生显著不良事件。多因素分析显示肿瘤直径、肿瘤分期和局部控制率是生存的独立影响因素。
要点
- 碘-125粒子近距离治疗宫颈癌体外放疗后非中央型盆腔复发可行,未发生显著不良事件。
- 肿瘤直径<5.3 cm和术后即刻D90>108.5 Gy与更好疗效相关。
- 肿瘤直径、肿瘤分期和局部控制率是生存的独立影响因素。
核心结论
- 碘-125粒子近距离治疗用于宫颈癌体外放疗后非中央型盆腔复发是可行的。
- 肿瘤直径<5.3 cm和术后即刻D90>108.5 Gy与更好疗效相关。
研究设计与样本
- 2015年6月至2022年4月间,32例患者共41个病灶接受碘-125粒子近距离治疗。
- 粒子在CT和/或3D打印模板图像引导下植入,中位剂量100 Gy(范围80-120 Gy)。
- 计算局部控制率和生存率,采用多因素logistic回归识别预后预测因素,采用受试者工作特征(ROC)曲线分析确定最佳截断值。
主要发现
- 中位随访48.52个月(范围4-86个月),6、12、24个月局部控制率分别为88.0%、63.2%、42.1%。
- 1年、2年生存率分别为36%、33%,中位生存时间13.26个月。
- 未发生显著不良事件。
- 多因素回归分析显示肿瘤直径、肿瘤分期和局部控制率是影响生存的独立因素。
- ROC曲线分析显示肿瘤直径和D90的曲线下面积分别为0.765和0.542,截断值分别为5.3 cm和108.5 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy of 125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy, and to analyze the clinical influential factors. METHODS: Between June 2015 and April 2022, 32 patients with 41 lesions were treated with 125I seed brachytherapy. The seeds were implanted under the guidance of CT and/or 3D-printed template images at a median dose of 100 Gy (range, 80-120 Gy), and the local control rate (LCR) and survival rates were calculated. We used multivariate logistic regression to identify prognosis predictors, and receiver operating characteristic (ROC) curve analysis to determine the optimal cut-off values. RESULTS: The median follow-up was 48.52 months (range, 4-86 months), and the 6-, 12-, and 24-month LCR was 88.0%, 63.2%, and 42.1%, respectively. The 1- and 2-year survival rates were 36% and 33%, respectively, and the median survival time was 13.26 months. No significant adverse events occurred. Multivariate regression analysis showed that tumor diameter, tumor stage, and LCR were independent factors influencing survival. ROC curve analysis showed that the area under the curve for tumor diameter and D90 were 0.765 and 0.542, respectively, with cut-off values of 5.3 cm and 108.5 Gy. CONCLUSIONS: The present findings indicate that 125I seed brachytherapy is feasible for treating non-central pelvic recurrence of cervical cancer after external beam radiotherapy. Further, tumor diameter < 5.3 cm and immediate postoperative D90 > 108.5 Gy were associated with better efficacy.
引用
- Di X, Gao Z, Yu H, et al. 125I seed brachytherapy for non-central pelvic recurrence of cervical cancer after external beam radiotherapy. Radiat Oncol. 2024. PMID: 38849839. doi:10.1186/s13014-024-02454-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。